Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 4

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  benign prostatic hyperplasia
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Evaluation of the effectiveness of laser photoselective vaporization of the prostate in the treatment of patients with benign prostatic hyperplasia

100%
Jedynak R., Piotrowicz G., Syryło T., Buczyński A., Zieliński H.
Folia Medica Cracoviensia
|
2018
|
vol. 58
|
issue 3
2
Publication available in full text mode
Content available

The effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia

88%
Socha P., Zduńczyk S., Tobolski D., Janowski T., Socha P., Zduńczyk S., Tobolski D., Janowski T.
Polish Journal of Veterinary Sciences
|
2018
|
vol. 21
|
issue 4
3
Publication available in full text mode
Content available

Thermobalancing therapy as a self-management tool

88%
Allen S.
World News of Natural Sciences
|
2019
|
vol. 23
84-93
EN
People live with one or more chronic diseases, medical and surgical treatments of which may affect their quality of life negatively. Thermobalancing therapy (TT) and Dr Allen’s therapeutic Devices (DATD) for the first time uses own body energy to treat chronic internal diseases. This invention received a US patent. Here we observe condition of people with benign prostatic hyperplasia (BPH), kidney stone disease and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) before and after use of TT and DATD. 10 years of empirical evidence has been studied in people with kidney disease, CP/CPPS and BPH. 2 clinical controlled trials on TT with DATD were conducted. The dynamics of clinical characteristics and parameters, such as pain, urinary symptoms and ultrasound prostate volume (PV), were compared with the no-treatment control groups. 124 men with BPH and 45 men with CP/CPPS used DATD for 6-month period, as mono-therapy, in clinical trials. The outcomes confirmed that TT with DATD reduced pain and PV in men with CP/CPPS and PV and urinary symptoms in men with BPH, while there were no positive changes in the control groups. 4 people with kidney stones, random from the 10-year follow-up, confirmed that after using DATD kidney stones were dissolved without side effects and complications. DATD is a class-1 medical device, which do not need an involvement of notified body, and it is easy use this device. Therefore, people with kidney stones, CP/CPPS and BPH should use DATD, as a tool for self-management in the first place.
4
Publication available in full text mode
Content available

PSA ciągle najlepszy marker nowotworowy, modyfi kacje testu i nowe markery raka stercza

51%
Braczkowski M., Białożyt M., Braczkowski R., Kondera-Anasz Z.
Annales Academiae Medicae Silesiensis
|
2011
|
vol. 65
|
issue 1-2
89-98
EN
The prostate-specific antigen is considered to be the most eff ective, though far from ideal, tumor marker. The basic aim of its application is to diagnose and diff erentiate between cancer and benign prostatic hyperplasia. The value of markers in case of prostate cancer is of particular importance, because of the long-term asymptomatic development. And recently, these values have become even more signifi cant, since there has been an increasing tendency to suff er from the disease. Our study presents advantages and imperfections of the PSA test, its modifi cations (e.g. dynamic tests) introduced in order to increase the specificity and sensitivity of the test, and thus its reliability. Subsequently proenzymes and PSA precursor forms as well as the opportunities for their use in the diagnostics are described. The rest of the article is devoted to the description of new potential prostate cancer markers, the implementation of which is closely associated with the development of molecular biology techniques. Among them the most important are: new kallikreins (PSA is also the member of kallikreins family), EPCA-2, PCA3, AMACR, products of gene fusion and rearrangements, GSTP1 hypermethlation, free non-cellular DNA and some antibodies.
PL
Od wielu lat specyficzny antygen sterczowy (PSA) uważany jest za najlepszy, choć daleki od ideału marker nowotworowy. Podstawowy cel jego zastosowania to pomoc w rozpoznawaniu i różnicowaniu raka i łagodnego przerostu gruczołu krokowego. Wartość markerów nowotworowych w przypadku raka stercza jest szczególnie ważna wobec faktu wieloletniego bezobjawowego rozwoju tego nowotworu, a szczególnego znaczenia nabiera ona w ostatnich latach, gdy obserwujemy stale wzrastającą tendencję do zachorowań. W pracy przedstawiono zalety i wady testu PSA, jego modyfikacje (np. testy dynamiczne) wprowadzone w celu zwiększenia czułości i specyficzności oraz – co za tym idzie – wiarygodności testu. W dalszej kolejności opisano proenzymy oraz formy prekursorowe PSA i możliwości wykorzystania ich w diagnostyce. W drugiej części pracy opisano nowe, potencjalne markery raka stercza, których próby wprowadzenia wiążą się z rozwojem technik biologii molekularnej. Należy tu wymienić kolejne kalikreiny (PSA jest także przedstawicielem tej rodziny), EPCA-2, PCA3, AMACR, produkty rearanżacji i fuzji genów, hipermetylacja GSTP1, wolne DNA w surowicy krwi, przeciwciała i szereg innych o nieco mniejszym znaczeniu.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.